share_log

騰盛博藥-B：截至2024年3月31日之股份發行人的證券變動月報表

BRII-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024

香港交易所 ·  Apr 7 22:25
Summary by Moomoo AI
騰盛博藥生物科技有限公司於2024年4月8日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股份變動情況。報告顯示，公司法定/註冊股本結存維持在1,200,000,000股，面值為0.000005美元，總額為6,000美元，本月無增減變動。股份期權方面，根據不同行使價的股份激勵計劃，有部分股份期權已行使或失效，但本月內新增發行的股份數目為1,500股，因行使期權所得資金總額為587.13港元。此外，公司亦根據股份獎勵計劃授出了受限制股份單位，但於2024年3月有231,625份受限制股份單位已失效。公司確認，所有證券發行均已獲董事會授權並符合相關上市規則要求。
騰盛博藥生物科技有限公司於2024年4月8日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股份變動情況。報告顯示，公司法定/註冊股本結存維持在1,200,000,000股，面值為0.000005美元，總額為6,000美元，本月無增減變動。股份期權方面，根據不同行使價的股份激勵計劃，有部分股份期權已行使或失效，但本月內新增發行的股份數目為1,500股，因行使期權所得資金總額為587.13港元。此外，公司亦根據股份獎勵計劃授出了受限制股份單位，但於2024年3月有231,625份受限制股份單位已失效。公司確認，所有證券發行均已獲董事會授權並符合相關上市規則要求。
Teng Sheng Bo Pharmaceutical Biotechnology Co., Ltd. filed with Hong Kong Trading and Settlement Limited on April 8, 2024 its latest Securities Change Month Report, reporting the company's stock changes as of March 31, 2024. THE REPORT SHOWED THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL REMAINED AT 1,200,000,000 SHARES WITH A FACE VALUE OF $0.00005 AND A TOTAL OF $6,000, WITH NO INCREASE OR DECREASE THIS MONTH. In terms of share options, some share options have been exercised or expired under share incentive schemes with different exercise prices, but the number of shares issued this month amounted to 1,500 shares for a total of HK$587.13. In addition, the Company has granted restricted shares under the Share Award Scheme, but 231,625 restricted units have expired as of March 2024. The Company confirms that all securities issuances have been authorized by the Board of Directors and meet the requirements of the relevant Listing Rules.
Teng Sheng Bo Pharmaceutical Biotechnology Co., Ltd. filed with Hong Kong Trading and Settlement Limited on April 8, 2024 its latest Securities Change Month Report, reporting the company's stock changes as of March 31, 2024. THE REPORT SHOWED THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL REMAINED AT 1,200,000,000 SHARES WITH A FACE VALUE OF $0.00005 AND A TOTAL OF $6,000, WITH NO INCREASE OR DECREASE THIS MONTH. In terms of share options, some share options have been exercised or expired under share incentive schemes with different exercise prices, but the number of shares issued this month amounted to 1,500 shares for a total of HK$587.13. In addition, the Company has granted restricted shares under the Share Award Scheme, but 231,625 restricted units have expired as of March 2024. The Company confirms that all securities issuances have been authorized by the Board of Directors and meet the requirements of the relevant Listing Rules.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more